After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.
FDA Approves Denosumab Biosimiliars for Prior Authorized Indications
Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma
T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses
Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.
FDA Approves Tislelizumab Combo for Advanced ESCC
The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.
Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma
Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.
Becoming Familiar With Patients’ AEs is Essential, Says Expert
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC